{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:25:30Z","timestamp":1790810730046,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["M2\/6"],"award-info":[{"award-number":["M2\/6"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13046-018-0952-7","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T22:43:43Z","timestamp":1543877023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity"],"prefix":"10.1186","volume":"37","author":[{"given":"Anna Maria","family":"Trotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Santagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Zanotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crescenzo","family":"D\u2019Alterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Camerlingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Lamantia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Anniciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Botti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Botti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisto","family":"Perdon\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Scala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"issue":"4","key":"952_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","volume":"1","author":"C Fitzmaurice","year":"2015","unstructured":"Fitzmaurice C, Dicker D, Pain A, et al. The global burden of Cancer 2013. JAMA Oncol. 2015;1(4):505\u201327.","journal-title":"JAMA Oncol"},{"issue":"1","key":"952_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"952_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.clgc.2013.04.018","volume":"11","author":"F Massari","year":"2013","unstructured":"Massari F, Bria E, Maines F, et al. Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. Clin Genitourin Cancer. 2013;11(4):471\u20136.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"952_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10585-012-9529-6","volume":"30","author":"E Herrmann","year":"2013","unstructured":"Herrmann E, Weishaupt C, Poppelmann B, et al. New tools for assessing the individual risk of metastasis in renal cell carcinoma. Clin Exp Metastasis. 2013;30(2):215\u201324.","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"952_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/path.1034","volume":"196","author":"P Schraml","year":"2002","unstructured":"Schraml P, Struckmann K, Hatz F, et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol. 2002;196(2):186\u201393.","journal-title":"J Pathol"},{"issue":"24","key":"952_CR6","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","volume":"22","author":"WY Kim","year":"2004","unstructured":"Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22(24):4991\u20135004.","journal-title":"J Clin Oncol"},{"issue":"24","key":"952_CR7","doi-asserted-by":"publisher","first-page":"7582","DOI":"10.1158\/1078-0432.CCR-09-2131","volume":"15","author":"AC Young","year":"2009","unstructured":"Young AC, Craven RA, Cohen D, et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res. 2009;15(24):7582\u201392.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"952_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrc3844","volume":"15","author":"L Gossage","year":"2015","unstructured":"Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"18 Pt 2","key":"952_CR9","doi-asserted-by":"publisher","first-page":"6290s","DOI":"10.1158\/1078-0432.CCR-sup-040025","volume":"10","author":"WG Kaelin Jr","year":"2004","unstructured":"Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004;10(18 Pt 2):6290s\u20135s.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"952_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/gcc.10054","volume":"34","author":"K Kondo","year":"2002","unstructured":"Kondo K, Yao M, Yoshida M, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer. 2002;34(1):58\u201368.","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"952_CR11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1158\/1078-0432.CCR-07-1753","volume":"14","author":"KM Smits","year":"2008","unstructured":"Smits KM, Schouten LJ, van Dijk BA, et al. Genetic and epigenetic alterations in the von hippel-Lindau gene: the influence on renal cancer prognosis. Clin Cancer Res. 2008;14(3):782\u20137.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"952_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ijc.23496","volume":"123","author":"JJ Patard","year":"2008","unstructured":"Patard JJ, Fergelot P, Karakiewicz PI, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 2008;123(2):395\u2013400.","journal-title":"Int J Cancer"},{"issue":"5","key":"952_CR13","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/1521-4141(200205)32:5<1205::AID-IMMU1205>3.0.CO;2-Y","volume":"32","author":"L Moretta","year":"2002","unstructured":"Moretta L, Bottino C, Pende D, et al. Human natural killer cells: their origin, receptors and function. Eur J Immunol. 2002;32(5):1205\u201311.","journal-title":"Eur J Immunol"},{"issue":"3","key":"952_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/cmi.2013.10","volume":"10","author":"M Cheng","year":"2013","unstructured":"Cheng M, Chen Y, Xiao W, et al. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013;10(3):230\u201352.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"952_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4161\/onci.1.1.18312","volume":"1","author":"G Fregni","year":"2012","unstructured":"Fregni G, Perier A, Avril MF, et al. NK cells sense tumors, course of disease and treatments: consequences for NK-based therapies. Oncoimmunology. 2012;1(1):38\u201347.","journal-title":"Oncoimmunology"},{"issue":"23","key":"952_CR16","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1158\/0008-5472.CAN-14-0303","volume":"74","author":"Y Messai","year":"2014","unstructured":"Messai Y, Noman MZ, Hasmim M, et al. ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy. Cancer Res. 2014;74(23):6820\u201332.","journal-title":"Cancer Res"},{"issue":"1","key":"952_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/IGC.0000000000000578","volume":"26","author":"WC Chang","year":"2016","unstructured":"Chang WC, Li CH, Chu LH, et al. Regulatory T cells suppress natural killer cell immunity in patients with human cervical carcinoma. Int J Gynecol Cancer. 2016;26(1):156\u201362.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"952_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.semcancer.2005.11.007","volume":"16","author":"RJ Orentas","year":"2006","unstructured":"Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin Cancer Biol. 2006;16(2):137\u201349.","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"952_CR19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1084\/jem.20051511","volume":"202","author":"F Ghiringhelli","year":"2005","unstructured":"Ghiringhelli F, Menard C, Terme M, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005;202(8):1075\u201385.","journal-title":"J Exp Med"},{"issue":"10","key":"952_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"RH Shoemaker","year":"2006","unstructured":"Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813\u201323.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"952_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1479-5876-3-11","volume":"3","author":"S Adams","year":"2005","unstructured":"Adams S, Robbins FM, Chen D, et al. HLA class I and II genotype of the NCI-60 cell lines. J Transl Med. 2005;3(1):11.","journal-title":"J Transl Med"},{"issue":"44","key":"952_CR22","doi-asserted-by":"publisher","first-page":"77110","DOI":"10.18632\/oncotarget.20363","volume":"8","author":"S Santagata","year":"2017","unstructured":"Santagata S, Napolitano M, D'Alterio C, et al. Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. Oncotarget. 2017;8(44):77110\u201320.","journal-title":"Oncotarget"},{"issue":"1\u20132","key":"952_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","volume":"294","author":"G Alter","year":"2004","unstructured":"Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294(1\u20132):15\u201322.","journal-title":"J Immunol Methods"},{"key":"952_CR24","first-page":"Unit7.39","volume":"Chapter 7","author":"M Claus","year":"2010","unstructured":"Claus M, Watzl C. Evaluation of human natural killer cell activities in whole blood. Curr Protoc Immunol. 2010;Chapter 7:Unit7.39.","journal-title":"Curr Protoc Immunol"},{"issue":"11","key":"952_CR25","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","volume":"115","author":"C Fauriat","year":"2010","unstructured":"Fauriat C, Long EO, Ljunggren HG, et al. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2010;115(11):2167\u201376.","journal-title":"Blood"},{"issue":"6","key":"952_CR26","first-page":"1092","volume":"55","author":"JM Whaley","year":"1994","unstructured":"Whaley JM, Naglich J, Gelbert L, et al. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet. 1994;55(6):1092\u2013102.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"952_CR27","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1593\/neo.09296","volume":"11","author":"G Sconocchia","year":"2009","unstructured":"Sconocchia G, Spagnoli GC, Del Principe D, et al. Defective infiltration of natural killer cells in MICA\/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. Neoplasia. 2009;11(7):662\u201371.","journal-title":"Neoplasia"},{"issue":"34","key":"952_CR28","doi-asserted-by":"publisher","first-page":"36245","DOI":"10.18632\/oncotarget.5768","volume":"6","author":"MB Morelli","year":"2015","unstructured":"Morelli MB, Amantini C, Santoni M, et al. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. Oncotarget. 2015;6(34):36245\u201359.","journal-title":"Oncotarget"},{"issue":"4","key":"952_CR29","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3892\/ijo.2016.3670","volume":"49","author":"Y Luan","year":"2016","unstructured":"Luan Y, Liu J, Liu X, et al. Tetramethypyrazine inhibits renal cell carcinoma cells through inhibition of NKG2D signaling pathways. Int J Oncol. 2016;49(4):1704\u201312.","journal-title":"Int J Oncol"},{"key":"952_CR30","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","volume":"8","author":"S Paul","year":"2017","unstructured":"Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in Cancer immunotherapy. Front Immunol. 2017;8:1124.","journal-title":"Front Immunol"},{"key":"952_CR31","doi-asserted-by":"publisher","first-page":"15165","DOI":"10.1038\/ncomms15165","volume":"8","author":"R Sinha","year":"2017","unstructured":"Sinha R, Winer AG, Chevinsky M, et al. Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. Nat Commun. 2017;8:15165.","journal-title":"Nat Commun"},{"key":"952_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/1479-5876-11-255","volume":"11","author":"L Campbell","year":"2013","unstructured":"Campbell L, Al-Jayyoussi G, Gutteridge R, et al. Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease. J Transl Med. 2013;11:255.","journal-title":"J Transl Med"},{"issue":"23","key":"952_CR33","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1038\/onc.2010.638","volume":"30","author":"A Perier","year":"2011","unstructured":"Perier A, Fregni G, Wittnebel S, et al. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Oncogene. 2011;30(23):2622\u201332.","journal-title":"Oncogene"},{"issue":"2","key":"952_CR34","doi-asserted-by":"publisher","first-page":"e985951","DOI":"10.4161\/2162402X.2014.985951","volume":"4","author":"Y Messai","year":"2015","unstructured":"Messai Y, Noman MZ, Hasmim M, et al. HIF-2alpha\/ITPR1 axis: a new saboteur of NK-mediated lysis. Oncoimmunology. 2015;4(2):e985951.","journal-title":"Oncoimmunology"},{"key":"952_CR35","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3389\/fimmu.2015.00482","volume":"6","author":"M Hasmim","year":"2015","unstructured":"Hasmim M, Messai Y, Ziani L, et al. Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress. Front Immunol. 2015;6:482.","journal-title":"Front Immunol"},{"key":"952_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nri3365","volume":"13","author":"H Spits","year":"2013","unstructured":"Spits H, Artis D, Colonna M, et al. Innate lymphoid cells\u2013a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13:145\u20139.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"952_CR37","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/ijc.11321","volume":"106","author":"JS Schleypen","year":"2003","unstructured":"Schleypen JS, Von Geldern M, Weiss E, et al. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer. 2003;106(6):905\u201312.","journal-title":"Int J Cancer"},{"issue":"3 Pt 1","key":"952_CR38","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1158\/1078-0432.CCR-05-0857","volume":"12","author":"JS Schleypen","year":"2006","unstructured":"Schleypen JS, Baur N, Kammerer R, et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res. 2006;12(3 Pt 1):718\u201325.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"952_CR39","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.4049\/jimmunol.1302464","volume":"192","author":"TK Connelley","year":"2014","unstructured":"Connelley TK, Longhi C, Burrells A, et al. NKp46+ CD3+ cells: a novel nonconventional T cell subset in cattle exhibiting both NK cell and T cell features. J Immunol. 2014;192(8):3868\u201380.","journal-title":"J Immunol"},{"key":"952_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fimmu.2013.00069","volume":"4","author":"K Hudspeth","year":"2013","unstructured":"Hudspeth K, Silva-Santos B, Mavilio D, et al. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol. 2013;4:69.","journal-title":"Front Immunol"},{"key":"952_CR41","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1172\/JCI43242","volume":"121","author":"J Yu","year":"2011","unstructured":"Yu J, Mitsui T, Wei M, et al. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. J Clin Invest. 2011;121:1456\u201370.","journal-title":"J Clin Invest"},{"issue":"3","key":"952_CR42","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/cmi.2013.2","volume":"10","author":"I Pedroza-Pacheco","year":"2013","unstructured":"Pedroza-Pacheco I, Madrigal A, Saudemont A. Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. Cell Mol Immunol. 2013;10(3):222\u20139.","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"952_CR43","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1002\/eji.200838813","volume":"38","author":"J Zimmer","year":"2008","unstructured":"Zimmer J, Andres E, Hentges F. NK cells and Treg cells: a fascinating dance cheek to cheek. Eur J Immunol. 2008;38(11):2942\u20135.","journal-title":"Eur J Immunol"},{"issue":"2","key":"952_CR44","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3892\/mmr.2014.2229","volume":"10","author":"Y Shen","year":"2014","unstructured":"Shen Y, Wang Q, Qi Y, et al. Peripheral Foxp3+ regulatory T cells and natural killer group 2, member D expression levels in natural killer cells of patients with colorectal cancer. Mol Med Rep. 2014;10(2):977\u201382.","journal-title":"Mol Med Rep"},{"issue":"4","key":"952_CR45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.eururo.2015.11.029","volume":"70","author":"Y Messai","year":"2016","unstructured":"Messai Y, Gad S, Noman MZ, et al. Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible Factor-2 alpha, is regulated by von Hippel-Lindau gene mutation status. Eur Urol. 2016;70(4):623\u201332.","journal-title":"Eur Urol"},{"issue":"13","key":"952_CR46","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","volume":"116","author":"DM Benson Jr","year":"2010","unstructured":"Benson DM Jr, Bakan CE, Mishra A, et al. The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116(13):2286\u201394.","journal-title":"Blood"},{"issue":"11","key":"952_CR47","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1158\/0008-5472.CAN-14-2788","volume":"75","author":"HB Jie","year":"2015","unstructured":"Jie HB, Schuler PJ, Lee SC, et al. CTLA-4(+) regulatory T cells increased in Cetuximab-treated head and neck Cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 2015;75(11):2200\u201310.","journal-title":"Cancer Res"},{"key":"952_CR48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ctrv.2017.11.008","volume":"63","author":"RL Ferris","year":"2018","unstructured":"Ferris RL, Lenz HJ, Trotta AM, et al. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2018;63:48\u201360.","journal-title":"Cancer Treat Rev"},{"key":"952_CR49","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-016-0374-y","volume":"10","author":"K Zarrabi","year":"2017","unstructured":"Zarrabi K, Fang C, Wu S. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. J Hematol Oncol. 2017;10:38.","journal-title":"J Hematol Oncol"},{"issue":"23","key":"952_CR50","doi-asserted-by":"publisher","first-page":"16334","DOI":"10.1074\/jbc.M112.437962","volume":"288","author":"F Stehle","year":"2013","unstructured":"Stehle F, Schulz K, Fahldieck C, et al. Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem. 2013 Jun 7;288(23):16334\u201347.","journal-title":"J Biol Chem"},{"key":"952_CR51","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.3892\/or.2014.3070","volume":"31","author":"K Geisler","year":"2014","unstructured":"Geisler K, Reischer A, Kroeger I, et al. Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model. Oncol Rep. 2014;31:2015\u201320.","journal-title":"Oncol Rep"},{"key":"952_CR52","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fimmu.2012.00388","volume":"3","author":"S Krieg","year":"2013","unstructured":"Krieg S, Ullrich E. Novel immune modulators used in hematology: impact on NK cells. Front Immunol. 2013 Jan 3;3:388.","journal-title":"Front Immunol"},{"key":"952_CR53","doi-asserted-by":"publisher","first-page":"8286","DOI":"10.4049\/jimmunol.0902404","volume":"183","author":"M Krusch","year":"2009","unstructured":"Krusch M, Salih J, Schlicke M, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol. 2009;183:8286\u201394.","journal-title":"J Immunol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0952-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-018-0952-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0952-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T19:04:10Z","timestamp":1575399850000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-018-0952-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1186\/s13046-018-0952-7","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"25 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Primary RCC samples were from the Department of Urology, National Cancer Institute \u201cG. Pascale\u201d (Naples, Italy) and Genitourinary Oncology and Rare Cancer Center, Federico II University (Naples, Italy). The research protocol was approved by Human Ethical Committee of Institute (n. CEI\/423\/13).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The author agree for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"297"}}